The impact of chronic kidney disease and short-term treatment with rosiglitazone on plasma cell-free DNA levels

Amanda Mcguire, Nadia Urosevic, D. Chan, G.K. Dogra, Tim Inglis, Aron Chakera

    Research output: Contribution to journalArticle

    7 Citations (Scopus)

    Abstract

    © 2014 Amanda L. McGuire et al. Patients with chronic kidney disease (CKD) are at increased risk of cardiovascular disease. Circulating free nucleic acids, known as cell-free DNA (cfDNA), have been proposed as a novel biomarker of cardiovascular risk. The impact of renal impairment on cfDNA levels and whether cfDNA is associated with endothelial dysfunction and inflammation in CKD has not been systematically studied. We analysed cfDNA concentrations from patients with varying degrees of CKD. In addition, to determine whether there is a relationship between cfDNA, inflammation, and endothelial dysfunction in CKD, levels of proinflammatory cytokines and von Willebrand Factor (vWF) were measured in patients treated with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone or placebo for 8 weeks. cfDNA levels were not increased with renal impairment or associated with the degree of renal dysfunction (P = 0.5). Treatment with rosiglitazone for 8 weeks, but not placebo, was more likely to lead to a reduction in cfDNA levels (P = 0.046); however, the absolute changes in cfDNA concentrations during treatment were not statistically significant (P > 0.05). cfDNA levels correlated with markers of endothelial dysfunction (hsCRP P = 0.0497) and vWF (P = 0.0005). In conclusion, cell-free DNA levels are not influenced by renal impairment but do reflect endothelial dysfunction in patients with CKD.
    Original languageEnglish
    Pages (from-to)1-8
    JournalPPAR Research
    Volume2014
    DOIs
    Publication statusPublished - 2014

    Fingerprint

    rosiglitazone
    Plasma Cells
    Chronic Renal Insufficiency
    DNA
    Kidney
    Therapeutics
    von Willebrand Factor
    Placebos
    Inflammation

    Cite this

    @article{72cb3cf233674d5e9a3c7ccb84d4160d,
    title = "The impact of chronic kidney disease and short-term treatment with rosiglitazone on plasma cell-free DNA levels",
    abstract = "{\circledC} 2014 Amanda L. McGuire et al. Patients with chronic kidney disease (CKD) are at increased risk of cardiovascular disease. Circulating free nucleic acids, known as cell-free DNA (cfDNA), have been proposed as a novel biomarker of cardiovascular risk. The impact of renal impairment on cfDNA levels and whether cfDNA is associated with endothelial dysfunction and inflammation in CKD has not been systematically studied. We analysed cfDNA concentrations from patients with varying degrees of CKD. In addition, to determine whether there is a relationship between cfDNA, inflammation, and endothelial dysfunction in CKD, levels of proinflammatory cytokines and von Willebrand Factor (vWF) were measured in patients treated with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone or placebo for 8 weeks. cfDNA levels were not increased with renal impairment or associated with the degree of renal dysfunction (P = 0.5). Treatment with rosiglitazone for 8 weeks, but not placebo, was more likely to lead to a reduction in cfDNA levels (P = 0.046); however, the absolute changes in cfDNA concentrations during treatment were not statistically significant (P > 0.05). cfDNA levels correlated with markers of endothelial dysfunction (hsCRP P = 0.0497) and vWF (P = 0.0005). In conclusion, cell-free DNA levels are not influenced by renal impairment but do reflect endothelial dysfunction in patients with CKD.",
    author = "Amanda Mcguire and Nadia Urosevic and D. Chan and G.K. Dogra and Tim Inglis and Aron Chakera",
    year = "2014",
    doi = "10.1155/2014/643189",
    language = "English",
    volume = "2014",
    pages = "1--8",
    journal = "PPAR Research",
    issn = "1687-4757",
    publisher = "Hindawi Publishing Corporation",

    }

    The impact of chronic kidney disease and short-term treatment with rosiglitazone on plasma cell-free DNA levels. / Mcguire, Amanda; Urosevic, Nadia; Chan, D.; Dogra, G.K.; Inglis, Tim; Chakera, Aron.

    In: PPAR Research, Vol. 2014, 2014, p. 1-8.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - The impact of chronic kidney disease and short-term treatment with rosiglitazone on plasma cell-free DNA levels

    AU - Mcguire, Amanda

    AU - Urosevic, Nadia

    AU - Chan, D.

    AU - Dogra, G.K.

    AU - Inglis, Tim

    AU - Chakera, Aron

    PY - 2014

    Y1 - 2014

    N2 - © 2014 Amanda L. McGuire et al. Patients with chronic kidney disease (CKD) are at increased risk of cardiovascular disease. Circulating free nucleic acids, known as cell-free DNA (cfDNA), have been proposed as a novel biomarker of cardiovascular risk. The impact of renal impairment on cfDNA levels and whether cfDNA is associated with endothelial dysfunction and inflammation in CKD has not been systematically studied. We analysed cfDNA concentrations from patients with varying degrees of CKD. In addition, to determine whether there is a relationship between cfDNA, inflammation, and endothelial dysfunction in CKD, levels of proinflammatory cytokines and von Willebrand Factor (vWF) were measured in patients treated with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone or placebo for 8 weeks. cfDNA levels were not increased with renal impairment or associated with the degree of renal dysfunction (P = 0.5). Treatment with rosiglitazone for 8 weeks, but not placebo, was more likely to lead to a reduction in cfDNA levels (P = 0.046); however, the absolute changes in cfDNA concentrations during treatment were not statistically significant (P > 0.05). cfDNA levels correlated with markers of endothelial dysfunction (hsCRP P = 0.0497) and vWF (P = 0.0005). In conclusion, cell-free DNA levels are not influenced by renal impairment but do reflect endothelial dysfunction in patients with CKD.

    AB - © 2014 Amanda L. McGuire et al. Patients with chronic kidney disease (CKD) are at increased risk of cardiovascular disease. Circulating free nucleic acids, known as cell-free DNA (cfDNA), have been proposed as a novel biomarker of cardiovascular risk. The impact of renal impairment on cfDNA levels and whether cfDNA is associated with endothelial dysfunction and inflammation in CKD has not been systematically studied. We analysed cfDNA concentrations from patients with varying degrees of CKD. In addition, to determine whether there is a relationship between cfDNA, inflammation, and endothelial dysfunction in CKD, levels of proinflammatory cytokines and von Willebrand Factor (vWF) were measured in patients treated with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone or placebo for 8 weeks. cfDNA levels were not increased with renal impairment or associated with the degree of renal dysfunction (P = 0.5). Treatment with rosiglitazone for 8 weeks, but not placebo, was more likely to lead to a reduction in cfDNA levels (P = 0.046); however, the absolute changes in cfDNA concentrations during treatment were not statistically significant (P > 0.05). cfDNA levels correlated with markers of endothelial dysfunction (hsCRP P = 0.0497) and vWF (P = 0.0005). In conclusion, cell-free DNA levels are not influenced by renal impairment but do reflect endothelial dysfunction in patients with CKD.

    U2 - 10.1155/2014/643189

    DO - 10.1155/2014/643189

    M3 - Article

    VL - 2014

    SP - 1

    EP - 8

    JO - PPAR Research

    JF - PPAR Research

    SN - 1687-4757

    ER -